There are 360 resources available
180P - Recalling pre-existing microbiota-specific T cells to target tumors
Presenter: Jean-Marie Carpier
Session: Poster Display
181P - SELECT: A phase 2 randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts)
Presenter: Mahmut Gumus
Session: Poster Display
182P - Cancer vaccines based on whole-tumor-lysate or neoepitopes with validated HLA-binding outperform those with predicted HLA-binding affinity
Presenter: Lana Kandalaft
Session: Poster Display
76P - Safety profile of adjuvant pembrolizumab (pembro) in melanoma, nonÐsmall cell lung cancer (NSCLC), and renal cell carcinoma (RCC): pooled analysis of phase 3 clinical trials
Presenter: Jason Luke
Session: Poster Display
183P - COMMANDER-001: Initial safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors
Presenter: Justin Moser
Session: Poster Display
184P - A Phase I Study of the cancer-specific vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response
Presenter: Nand Singh
Session: Poster Display
78P - Clinical outcomes with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC).
Presenter: MARA PERSANO
Session: Poster Display